文献速递哮喘

新西兰与澳大利亚哮喘人群中ICS/LABA使用比例与哮喘结局的横断面调查

Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia.
PubMed 文献 · Respirology · 2017-08-09

该研究基于2012年澳大利亚和2013年新西兰的全国代表性网络调查,纳入≥16岁当前哮喘患者(新西兰537例,澳大利亚2686例),比较两国哮喘管理与结局。新西兰含ICS药物使用率高于澳大利亚(68.8% vs 60.9%,P=0.006),但ICS/LABA占ICS总使用比例新西兰低于澳大利亚(44.4% vs 81.5%,P<0.0001)。两国ACT评分相似(P=0.41),症状良好控制比例分别为58.6%和54.4%,急诊就诊比例相似(27.9%和28.6%,P=0.75)。

要点

  • 新西兰含ICS药物使用率高于澳大利亚,但ICS/LABA占比远低于澳大利亚。
  • 两国ACT评分及症状良好控制比例相似,急诊就诊比例无差异。
  • 新西兰ICS/LABA依从性高于澳大利亚,且ICS/LABA依从性高于单用ICS。

核心结论

  • 两国哮喘控制不佳均常见,尽管含ICS药物有补贴。
  • 新西兰相对更多使用单用ICS而非ICS/LABA,未损害人群层面哮喘结局,可能与新西兰依从性更好有关。
  • 不同ICS/LABA补贴标准和患者共付费用也可能 contribute 于这些发现。

研究设计与样本

  • 研究为基于网络面板的横断面调查,对象为≥16岁当前哮喘患者。
  • 澳大利亚2012年调查纳入2686例,新西兰2013年调查纳入537例,按全国人口比例分层随机抽取。
  • 症状控制采用哮喘控制测试(ACT)评估,医疗利用基于过去一年报告的紧急医生/医院就诊。

主要发现

  • 新西兰含ICS药物使用率为68.8%,澳大利亚为60.9%(P=0.006)。
  • ICS/LABA占ICS总使用比例新西兰为44.4%,澳大利亚为81.5%(P<0.0001)。
  • ICS/LABA依从性高于单用ICS(P<0.0001),且新西兰依从性高于澳大利亚(P<0.0001)。
  • ACT评分两国相似(P=0.41),症状良好控制比例分别为58.6%和54.4%。
  • 新西兰非紧急哮喘复查报告率高于澳大利亚(56.6% vs 50.4%,P=0.009),紧急哮喘就诊比例相似(27.9% vs 28.6%,P=0.75)。

临床怎么用

  • 在评估哮喘管理质量时,应同时关注ICS/LABA使用比例与患者依从性,而非仅关注药物选择。
  • 补贴政策和患者共付费用可能影响ICS/LABA使用模式,临床决策需结合可及性。

局限性

  • 原文未明确报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: New Zealand (NZ) and Australia (AU) have similarly high asthma prevalence; both have universal public health systems, but different criteria for subsidized medicines. We explored differences in asthma management and asthma-related outcomes between these countries. METHODS: A web-based survey was administered in AU (2012) and NZ (2013) to individuals aged ≥16 years with current asthma, drawn randomly from web-based panels, stratified by national population proportions. Symptom control was assessed with the Asthma Control Test (ACT). Healthcare utilization was assessed from reported urgent doctor/hospital visits in the previous year. RESULTS: NZ (n = 537) and Australian (n = 2686) participants had similar age and gender distribution. More NZ than Australian participants used inhaled corticosteroid (ICS)-containing medication (68.8% vs 60.9%; P = 0.006) but ICS/long-acting β2 -agonist (LABA) constituted 44.4% of NZ and 81.5% of Australian total ICS use (P < 0.0001). Adherence was higher with ICS/LABA than ICS-alone (P < 0.0001), and higher in NZ than in AU (P < 0.0001). ACT scores were similar (P = 0.41), with symptoms well controlled in 58.6% and 54.4% participants, respectively. More NZ participants reported non-urgent asthma reviews (56.6% vs 50.4%; P = 0.009). Similar proportions had urgent asthma visits (27.9% and 28.6%, respectively, P = 0.75). CONCLUSION: This comparison, which included the first nationally representative data for asthma control in NZ, showed that poorly controlled asthma is common in both NZ and AU, despite subsidized ICS-containing medications. The greater use of ICS-alone in NZ relative to ICS/LABA does not appear to have compromised population-level asthma outcomes, perhaps due to better adherence in NZ. Different ICS/LABA subsidy criteria and different patient copayments may also have contributed to these findings.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Reddel HK, Beckert L, Moran A, et al. Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia. Respirology. 2017. PMID: 28791752. doi:10.1111/resp.13123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。